MAPT and Alzheimer disease: Fluid biomarkers, such as plasma amyloid-β and tau, offer a less invasive and more cost-effective approach for AD diagnosis and monitoring (Gillespie, 2022;, Toledo, 2013;, Ferreira, 2023).